Original article by Jared Lynch
The Australian – Page: 17 & 27 : 13-Feb-20
CSL has posted a 2019-20 interim net profit of $US1.248bn, which is eight per cent higher than previously. Sales rose by 8.4 per cent to $US4.7bn, with sales of its immunoglobulin products rising by 26 per cent to $US1.985bn. The biotechnology group expects its full-year profit to be within the range of $US2.1bn to $US2.17bn. CEO Paul Perreault says none of the company’s employees in Wuhan have been infected by the coronavirus and the company has not yet been impacted by the outbreak.
CSL LIMITED – ASX CSL